NXL

Accepted abstracts showcase Nexalin’s proprietary DIFS™ 15 mA 77.5 Hz treatment platform and clinical improvements across anxiety, depression, insomnia and quality of life Data to be presented include 77.8% anxiety response rate at end of treatment, durable benefits maintained at 8-week follow-up and no serious adverse events, seizures or manic/hypomanic switches reported Presentations of clinical data further strengthen the scientific viability of Nexalin’s new proprietary non-invasive approach to deep-brain frequency-based neurostimulation as the Company prepares for global commercial initiatives HOUSTON, TX, June 16, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that two clinical abstracts evaluating Nexalin’s proprietary DIFS™ 15 mA, 77.5 Hz treatment platform have been accepted for presentation at the 2026 NYC Neuromodulation Conference. The accepted abstracts are titled: “Transcranial Alternating Current Stimulation for the Treatment of Anxiety: Preliminary Results from an Open-Label Pilot Clinical Trial” “Transcranial Alternating Current Stimulation for Comorbid Anxiety and Insomnia: Preliminary Findings on Insomnia and Quality of Life from an Open-Label Pilot Trial” The accepted abstracts are based on data from the Company’s recently completed 8-week, single-center, prospective, clinical trial conducted at the Institute of Psychiatry, Hospital das Clínicas, University of São Paulo. Adults with generalized anxiety disorder and comorbid insomnia received 20 sessions of Nexalin’s proprietary 15 mAmp deep-brain frequency stimulation over four weeks, followed by a four-week follow-up period. Each 40-minute session was administered using the Nexalin DIFS™ device at 15 mA and 77.5 Hz. “The acceptance of two Nexalin-related clinical abstracts for presentation at the 2026 NYC Neuromodulation Conference is another important milestone for our proprietary non-invasive treatment platform,” said Mark White, Chief Executive Officer of Nexalin Technology. “These presentations will showcase Nexalin’s clinical results to a highly relevant scientific and medical audience, while underscoring what we believe may represent a distinction between Nexalin and all other competitors in the field: Nexalin is not advancing a con...

Study using Nexalin’s proprietary DIFS™ 15 mA 77.5 Hz treatment platform demonstrated rapid, large-magnitude improvements in anxiety and depression with benefits maintained at 8-week follow-up Results further validate Nexalin’s prior clinical data and support the Company’s differentiated, non-invasive approach to deep frequency-based neurostimulation No serious adverse events, seizures or manic/hypomanic switches were reported, reinforcing the favorable tolerability profile of Nexalin’s technology HOUSTON, June 10, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the successful completion of an 8-week, single-center, prospective, open-label clinical trial evaluating Nexalin’s proprietary 15 milliamp (mA), 77.5 Hz neurostimulation protocol in adults with generalized anxiety disorder and comorbid insomnia. The clinical trial was conducted at the Institute of Psychiatry, Hospital das Clínicas, University of São Paulo. Participants received 20 sessions of transcranial alternating current stimulation over four weeks, followed by a four-week follow-up period. Each 40-minute session was administered using the Nexalin DIFS™ device at 15 mA and 77.5 Hz. The completed trial demonstrated rapid, large-magnitude and durable improvements across multiple high-burden neuropsychiatric domains, including anxiety, depressive symptoms, insomnia and quality of life. Importantly, improvements were observed early in the treatment course, continued through the end of treatment, and were maintained at 8-week follow-up. “This is another major clinical milestone for Nexalin and another powerful validation point for our proprietary non-invasive treatment platform,” said Mark White, Chief Executive Officer of Nexalin Technology. “These results continue to affirm the positive clinical signals observed in prior Nexalin studies and strengthen our conviction that Nexalin is developing a fundamentally differentiated and advanced neuro-technology platform, not a ‘me-too’ neurostimulation device. We believe our non-invasive, frequency-based approach has the potential to represent a breakthrough in the treatment of neuropsychiatric conditions where patients urgently need new options.” Key results from the completed pilot trial include: 77.8% anxie...

Peer-reviewed case report published in The American Journal on Addictions highlights significant clinical improvement and sustained abstinence following Nexalin’s non-invasive therapy HOUSTON, TX, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the publication of an independent, peer-reviewed study in The American Journal on Addictions titled “High-intensity transcranial alternating current stimulation for gambling disorder comorbidities with alcohol use disorders: A case report.” The study evaluated the safety and efficacy of Nexalin’s 15 milliamp (mA) neurostimulation device in a patient diagnosed with both gambling disorder (GD) and alcohol use disorder (AUD). Following 20 outpatient treatment sessions over 10 days, the patient achieved complete abstinence from gambling and alcohol, along with marked improvement in cognitive control and no adverse effects during a three-month follow-up period. According to the authors, Nexalin’s device “is a safe, efficacious potential treatment for GD-AUD comorbidity,” marking the first published clinical application of this technology for a dual-diagnosis condition. The researchers further noted that “the intervention was well-tolerated” and that improvements in cognitive function appeared to precede sustained behavioral change, suggesting a neuroplastic mechanism involving deeper brain network modulation. The case was conducted by investigators at the Shanghai Mental Health Center, part of Shanghai Jiao Tong University School of Medicine, using the Nexalin system, which is approved in China for the treatment of depression and insomnia. Each session delivered a 15 mA current at 77.5 Hz for 40 minutes. The study was registered on ClinicalTrials.gov (Identifier: NCT06195995) and received prior ethics approval. “This publication reinforces what we believe to be the growing scientific validation of Nexalin’s 15 mA device as a non-pharmacological approach for addressing addiction and other complex neuropsychiatric conditions,” said Mark White, CEO of Nexalin Technology, Inc. “These results underscore how Nexalin’s frequency-based neurostimulation represents a breakthrough in non-invasive stimulation of the brain. Nexalin’s proprietary approach to brain health safely modulates dist...

40-Hz DIFS™ significantly improves cognitive performance and brain connectivity in peer-reviewed clinical trial Results published in Radiology, the flagship journal of the Radiological Society of North America (RSNA) HOUSTON, TX, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the publication of additional positive clinical data in Radiology demonstrating that its proprietary 15 milliamp (mA) Gen-2 Nexalin DIFS™ technology—Nexalin’s advanced implementation of transcranial alternating current stimulation (tACS)—improves cognitive performance and enhances brain network connectivity in patients with mild Alzheimer’s disease (AD). The randomized, sham-controlled trial provides the strongest peer-reviewed evidence to date of a non-invasive, drug-free intervention delivering measurable neurological and clinical benefits in AD. The full study is available here: https://pubs.rsna.org/doi/10.1148/radiol.241463. Key Findings from the Clinical Study: Clinically Meaningful Cognitive Gains: Patients receiving Nexalin’s Gen-2 SYNC 40-Hz DIFS device showed a significant improvement in Mini-Mental State Examination (MMSE) scores and additional significant improvement in Montreal Cognitive Assessment (MoCA) scores compared to baseline. These improvements were statistically significant when compared to the sham group (P = .001 and .03, respectively). Neuroimaging-Confirmed Mechanism: Resting-state functional MRI (fMRI) revealed enhanced functional connectivity (FC) between the hippocampus and key cortical regions, including the middle cingulate gyrus and middle frontal gyrus, both of which are critical to memory and executive function. Network-Level Effects: Statistically significant increases in FC were also observed across broader cognitive networks, including the default mode network (DMN), frontoparietal networks (FPN), and visual and auditory systems, which are commonly disrupted in Alzheimer’s disease. Correlated Cognitive Gains: Increased connectivity between the hippocampus and middle cingulate gyrus was significantly correlated with improvement on the Boston Naming Test, providing further evidence of the link between brain network modulation and functional outcomes (r = 0.65, FDR-adjusted P = .008). Excellent Safety...

Nexalin Technology (NXL) shares rose 68% in recent Wednesday trading after the company said data fro